INCREASED SOLUBLE SERUM CD163 (SCD163) LEVELS PREDICT A SHORT DISEASE FREE SURVIVAL IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)

Introduction: Monocyte counts were found of prognostic significance in DLBCL, implying the possible contribution monocyte-macrophage lineage cells disease pathogenesis. These secrete among others sCD163, role which has not been investigated yet. Aims: To study eventual correlation serum sCD163 levels with prognosis DLBCL. Patients and Methods: Twenty-six DLBCL patients studied a median follow-up time 21 months (2–138). Ten diagnosed early stages (1 2) while resting majority was advanced (3 4). Six (23%) relapsed during course. Seven succumbed to their other 3 from causes. SerumCD163 measurements performed by ELISA (Duo-Set R&D Quantiquine) according manufacturer’s instructions frozen sera kept at diagnosis. The SPSS v.26 software used for statistical analysis survival curves drawn Kaplan-Mayer method compared log-rank test. Results: Serum ranged 34072 164912 pg/mL (median 134672 pg/mL) 104420 >140000 117952 15 healthy individuals. above had higher probability relapse shorter free (p = 0.004), (figure). Overall affected levels. Keywords: aggressive B-cell non-Hodgkin lymphoma, diagnostic biomarkers, targeting tumor microenvironment No conflicts interests pertinent abstract.